Profitability Metrics

Gross Margin
401.95%
Operating Margin
48.91%
Net Margin
6.31%

Efficiency Metrics

Revenue per Expense Ratio
1.96
R&D as % of Revenue
0.00%

Earnings Quality

EBITDA Margin
0.00%
Income Tax Rate
37.57%
EPS
31.1200000000

Balance Sheet Analysis

Current Ratio
0.24
Cash Ratio
-0.23
Working Capital
$-99,679.49B
Debt to Equity
3.91
Debt to Assets
21.76%
Equity Ratio
5.57%

Cash Flow Analysis

Operating Cash Flow Ratio
15.46%
Free Cash Flow Ratio
4.37%
CapEx to Revenue
11.09%
Dividends Paid
$766.54B
Stock Buybacks
No buybacks
Total Shareholder Returns
$766.54B
Cash Position Change
9.19%

Key Takeaways (2023 FY)

  • Revenue declined by 28.183114566154%, indicating potential market challenges
  • Increased dividend payments by 80.35%

Detailed Growth Metrics

Core Performance

Revenue
-28.18%
Net Income
-81.54%
EPS
-82.01%
Operating Income
-65.10%

Operational Efficiency

R&D Expenses
0.00%
SG&A Expenses
-38.03%
Operating Cash Flow
915.12%
Free Cash Flow
137.40%

Balance Sheet Health

Assets
1.89%
Debt
-9.12%
Book Value per Share
-0.32%
Inventory
100.00%

Shareholder Returns

Dividends per Share
80.35%
Shares Outstanding
2.60%

Long Term Trends

3Y Revenue/Share
-52.37%
5Y Revenue/Share
-98.18%
3Y Dividend/Share
-45.93%
5Y Dividend/Share
-97.83%